Latest Phase II results validate Circassia's cat allergy treatment
This article was originally published in Scrip
Executive Summary
Circassia, the specialty biopharmaceutical company based in the UK and developing a new class of T cell vaccines to treat allergies and combat organ transplant rejection, has reported another set of positive results from Phase II trials with its lead R&D programme, the ToleroMune cat allergy treatment.
You may also be interested in...
HemaQuest expands Phase II remit for HQK-1001 in sickle cell disease
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis withdraws European application for 'personalised' lumiracoxib
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Avantium Pharma buyout creates new CRO Crystallics
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.
Need a specific report? 1000+ reports available
Buy Reports